On Jan. 30, 2026 BioIVT hosted a virtual panel featuring representatives from FDA, industry and NAM development for a unique, candid conversation about what’s working, what’s missing, and what comes next for the implementation of NAMs in research and development.

Regulatory agencies and industry innovators are accelerating the push to utilize scientifically validated New Approach Methodologies (NAMs), which aim to provide more human-relevant preclinical drug safety and efficacy data while eliminating unnecessary animal testing. Over the past decade, we’ve seen rapid scientific progress in the development of NAMs, but we are now entering a pivotal phase as we transition into implementation.

This event explored the scientific, operational, and regulatory steps needed to integrate NAMs into modern drug development. The panel discussed the scientific readiness of NAMs, the barriers that remain, the value of collaborative frameworks, and look into what it will take for these models to scale across the industry.

Although a recording of the event is not available, we have prepared an article to share the key discussion points with those who were unable to attend. Please use the registration form below to access the recap.